natgillin/translations-raw huggingface dataset:
Safety and immunogenicity data in healthy adults, including older people.
Podatki o varnosti in imunogenosti pri zdravih odraslih, vključno s starostniki.
Safety and immunogenicity data in healthy children and adolescents aged from 6 months to 17 years and in adults, including the elderly
Podatke o varnosti in imunogenosti za zdrave otroke in mladostnike v starosti od 6 mescev do 17 let ter odrasle osebe, vključno s starostniki.
Safety and immunogenicity data in special risk groups (immunocompromised and chronically ill)
Podatki o varnosti in imunogenosti pri skupinah s posebnim tveganjem (imunsko kompromitiranih osebah in bolnikih s kroničnimi boleznimi).
Safety and immunogenicity data obtained after administration of a one or two doses of Focetria H1N1v to healthy children and adolescents aged 6 months-17 years and to healthy adults, including the elderly.
Podatki o varnosti in imunogenosti, dobljeni tri tedne po uporabi enega ali dveh odmerkov cepiva Focetria H1N1v pri zdravih otrocih in mladostnikih v starosti 6 mesecev-17 let in zdravih odraslih oseb, vključno s starostniki.
Safety and immunogenicity data obtained after administration of one or two doses of Focetria H1N1v to healthy children and adolescents aged 6 months-17 years and to healthy adults, including the elderly.
Podatki o varnosti in imunogenosti, dobljeni po uporabi enega ali dveh odmerkov cepiva Focetria (H1N1) pri zdravih otrocih in mladostnikih v starosti 6 mesecev-17 let in zdravih odraslih oseb, vključno s starostniki.
Safety and immunogenicity data obtained three weeks after administration of two doses of Celvapan (H1N1)v to healthy children aged 6 months to 17 years.
Podatki o varnosti in imunogenosti, dobljenih tri tedne po dajanju dveh odmerkov cepiva Celvapan (H1N1)v zdravim otrokom, starim od 6 mesecev do 17 let.
Safety and immunogenicity have not been assessed in patients with increased susceptibility to meningococcal infection due to conditions such as terminal complement deficiencies and anatomic or functional asplenia.
Pri bolnikih z zvečano dovzetnostjo za meningokokne okužbe zaradi motenj, kot so pomanjkanja terminalnega komplementa in anatomska ali funkcijska asplenija, varnost in imunogenost nista bili ocenjeni.
Safety and immunogenicity of a qHPV vaccine have been assessed in individuals aged from 7 to 12 years who are known to be infected with human immunodeficiency virus (HIV) (see section 5.1).
Varnost in imunogenost qHPV cepiva sta bili ovrednoteni pri posameznikih, starih od 7 do 12 let, za katere je bilo znano, da so okuženi z virusom humane imunske pomanjkljivosti (HIV) (glejte poglavje 5.1).
Safety and pharmacodynamic results in these patients are consistent with results observed in patients 5 to 57 years old (see sections 4.8).
Rezultati varnosti in farmakodinamični rezultati pri teh bolnikih so v skladu z rezultati, ki so jih opazili pri bolnikih, starih od 5 do 57 let (glejte poglavje 4.8).
Safety and tolerability of bosentan was investigated in an exploratory, uncontrolled 12-week study in 11 patients with pulmonary hypertension secondary to severe COPD (stage III of GOLD classification).
Varnost in prenašanje bosentana so raziskali v raziskovalni, nekontrolirani 12-tedenski študiji z 11 bolniki s sekundarno pljučno hipertenzijo kot posledico hude KOPB (stopnja III po razvrstitvi GOLD).
Safety and tolerability over an extended 12-week period
Varnost in prenašanje med 12-tedenskim podaljšanjem
SAFETY ASPECTS
VARNOSTNI VIDIKI
Safety assessment was made based on 491 acromegaly patients who received pasireotide (419 patients received pasireotide intramuscular use and 72 received pasireotide subcutaneous use) in phase I, II and III studies.
Ocena varnosti temelji na študijah faze I, II in III pri 491 bolnikih z akromegalijo, ki so prejemali pasireotid (419 bolnikov je prejemalo pasireotid za intramuskularno uporabo in 72 pasireotid za subkutano uporabo).
Safety Assessments at each visit including QT prolongation information.
Ocena varnosti ob vsakem obisku, vključno s podatki o podaljšanju intervala QT.
Safety cover fully retracted
Varnostni pokrovček umaknjen
Safety cover out
Varnostni pokrovček na mestu
Safety data after the first and second dose in children and adolescents with a similar pandemic vaccine (Focetria H1N1v) suggest a comparable safety profile with that reported for the aH5N1 mock-up vaccine formulation (Foclivia).
Varnostni podatki po prvem in drugem odmerku pri otrocih in mladostnikih s podobnim cepivom (Focetria H1N1v) kažejo varnostni profil, ki je primerljiv z varnostnim profilom demonstracijskega cepiva proti aH5N1 (Foclivia).
Safety data after the first and second vaccination suggest a similar safety profile to that reported for the influenza vaccines using a H5N1 strain.
Podatki o varnosti po prvem in drugem cepljenju kažejo podoben varnostni profil kot pri cepivih proti gripi s sevom H5N1.
Safety data are available, however, in pregnant women exposed to Focetria (an H1N1 pandemic vaccine similar to Foclivia which contains the same amount of MF59C.1 as Foclivia.
Varnostni podatki pa so na voljo za nosečnice, ki so bile izpostavljene zdravilu Focetria (cepivo proti pandemični gripi H1N1, ki vsebuje adjuvans MF59.1 in je podobno zdravilu Focetria).
Safety data are based on patients with haematological malignancies enrolled in randomised, placebo- controlled clinical studies, including one pharmacokinetic study, and post marketing experience.
Podatki o varnosti temeljijo na izsledkih, dobljenih pri bolnikih s hematološkimi malignomi, vključenih v randomizirane, s placebom kontrolirane klinične študije, vključno s študijo farmakokinetike, in na podlagi izkušenj v obdobju trženja.
Safety data are presented based on an integrated data set of 682 patients with relapsed lung cancer administered 2536 courses of oral topotecan monotherapy (275 patients with relapsed SCLC and 407 with relapsed non-SCLC).
Podatki o varnosti so navedeni na podlagi celotnega nabora podatkov 682 bolnikov z relapsom pljučnega raka, ki so dobili 2536 ciklusov monoterapije s peroralnim topotekanom (275 bolnikov z relapsom drobnoceličnega pljučnega raka in 407 bolnikov z relapsom nedrobnoceličnega pljučnega raka).
Safety data are presented based on an integrated data set of 682 patients with relapsed lung cancer administered 2536 courses of oral topotecan monotherapy (275 patients with relapsed SCLC and 407 with relapsed non-SCLC).
Ti podatki o varnosti predstavljajo celoten nabor podatkov o 682 bolnikih z relapsom pljučnega raka, ki so dobili 2536 ciklusov monoterapije s peroralnim topotekanom (275 bolnikov z relapsom drobnoceličnega pljučnega raka in 407 bolnikov z relapsom nedrobnoceličnega pljučnega raka).
Safety data for amlodipine are well established both clinically and non-clinically.
Podatki o varnosti uporabe amlodipina so ustrezno potrjeni tako v kliničnih kot predkliničnih študijah.
Safety data included all the patient visits up to the point in time when the last patient completed 144 weeks in the trial.
Podatki o varnosti zajemajo vse obiske bolnikov do trenutka, ko je zadnji zaključil 144-tedensko sodelovanje v raziskavi.
Safety data regarding use of Fluenz Tetra are based on data from Fluenz Tetra clinical studies in 1,382 children and adolescents 2 to 17 years of age, Fluenz clinical studies in over 29,000 children and adolescents 2 to 17 years of age and Fluenz post-authorisation safety studies in over 84,000 children and adolescents 2 to 17 years of age.
Varnostni podatki o uporabi cepiva Fluenz Tetra temeljijo na kliničnih študijah cepiva Fluenz Tetra, ki so vključevale 1.382 otrok in mladostnikov starih od 2 do 17 let, kliničnih študijah cepiva Fluenz, ki so vključevale več kot 29.000 otrok in mladostnikov starih od 2 do 17 let in na varnostnih študijah cepiva Fluenz po začetku trženja, ki so vključevale več kot 84.000 otrok in mladostnikov starih od 2 do 17 let.
Safety data were collected for 194 paediatric patients with CF aged 12 to 17 years who are homozygous for the F508del mutation and who received lumacaftor/ivacaftor in the placebo-controlled, Phase 3 studies.
Varnostne podatke so zbrali pri 194 pediatričnih bolnikih s CF, starih 12 do 17 let, ki so bili homozigotni za mutacijo F508del in ki so prejemali lumakaftor/ivakaftor v študijah 3. faze, kontroliranih s placebom.
Safety evaluation of Tarceva is based on the data from more than 1500 patients treated with at least one 150 mg dose of Tarceva monotherapy and more than 300 patients who received Tarceva 100 or 150 mg in combination with gemcitabine.
Varnost zdravila Tarceva so vrednotili na osnovi podatkov pri več kot 1500 bolnikih, ki so prejeli najmanj en 150 mg odmerek zdravila Tarceva kot samostojno zdravilo, in več kot 300 bolnikih, ki so prejemali zdravilo Tarceva 100 mg ali 150 mg v kombinaciji z gemcitabinom.
Safety features will be implemented until 9/2/2019.
Zaščitni elementi bodo uvedeni do 9.
Safety guard
Varnostna zaščita
Safety guard down after use.
nim dravilo nim dravilo
Safety guard down after use.
Varnostna zaščita je po uporabi pomaknjena dol
Safety has also been evaluated in 584 female partners of these subjects.
Varnost je bila ocenjena tudi pri 584 partnerkah teh preiskovancev.
Safety has been demonstrated with up to 5 times the recommended dose in healthy adult dogs (treated up to 6 times at two-week intervals) and in puppies (aged 8 weeks treated once).
Varnost zdravila je bila ugotovljena za do 5-kratni priporočeni odmerek pri zdravih odraslih psih (zdravljenih do 6-krat v dvotedenskih intervalih) in pri mladičih (starih 8 tednov ali več, zdravljenih enkrat).
Safety in patients with left ventricular ejection fraction (LVEF) < 50% or NYHA Class III or IV heart failure (in study 301) or NYHA Class II to IV heart failure (in study 302) was not established (see sections 4.8 and 5.1).
Pri bolnikih z iztisnim deležem levega prekata (LVEF – left ventricular ejection fraction) < 50% ali s srčnim popuščanjem razreda III ali IV (študija 301) ali s srčnim popuščanjem razreda II do IV (študija 302) po klasifikaciji NYHA varnosti uporabe zdravila ZYTIGA niso dokazali (glejte poglavji 4.8 in 5.1).
Safety in pediatric RA (JIA) patients
Varnost pri pediatričnih bolnikih z RA (JIA)
Safety in preterm infants:
Varnost pri nedonošenčkih:
Safety information for Rasilamlo in patients aged 75 years and older is limited.
Podatkov o varnosti uporabe zdravila Rasilamlo pri bolnikih, ki so stari 75 let ali več, je malo.
Safety information has been included in the summary of product characteristics and the package leaflet for Simparica, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
Safety information has been included in the summary of product characteristics and the package leaflet for ZACTRAN, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
V povzetek glavnih značilnosti zdravila ZACTRAN in navodilo za njegovo uporabo so bile vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in lastniki ali skrbniki živali.
Safety margins for peripheral nerve effects in rats and dogs are 8- and 6-fold, respectively, based on comparison of Cmax values at the No Observed Effect Level (NOEL) with the Cmax achieved on dosing with 30-minute intravenous infusion of 6 mg/kg once daily in patients with normal renal function.
Glede učinkov na periferne živce je določanje še varnih odmerkov temeljilo na primerjavi med 8-kratno (pri podganah) oziroma 6-kratno (pri psih) vrednostjo Cmax pri odmerku brez opaženih učinkov (No Observed Effect Level - NOEL) in med Cmax pri odmerjanju 6 mg/kg enkrat dnevno s 30-minutno intravensko infuzijo pri bolnikih z normalnim delovanjem ledvic.
Safety margins for the chronic rat and dog studies ranged between 8-fold and 15-fold using total plasma exposure and 1- to 2-fold using unbound (free fraction) plasma exposures.
Varnostne meje za študije pri podganah in psih s kronično obliko bolezni so bile določene pri 8- in 15- kratniku vrednosti z uporabo celokupne plazemske izpostavljenosti ter pri 1- do 2-kratniku vrednosti z uporabo plazemske izpostavljenosti nevezanih (prostih) delov.
Safety needle
varnostna igla
Safety needles (BD SafetyGlideTM) for connection to each barrel are also provided.
Priloženi sta tudi varnostni igli (BD SafetyGlide™) za povezavo z valjema.
Safety of Advocate when administered on the same day as an adulticide to remove adult heartworms has not been evaluated.
Varnost zdravila Advocate, če ga dajemo isti dan kot sredstva, ki uničujejo odrasle oblike srčnih glist, ni bila ocenjena.
Safety of combination not established; combination not recommended
ugotovili, zato jemanja te kombinacije ne priporočamo.
Safety of Picato 150 mcg/g treatment for 3 days or Picato 500 mcg/g treatment for 2 days was assessed up to day 57, the majority of the reported adverse reactions and local skin responses were mild to moderate in intensity and all resolved without sequelae.
Varnost 3-dnevnega zdravljenja z zdravilom Picato 150 µg/g in 2-dnevnega zdravljenja z zdravilom Picato 500 µg/g so proučevali 57 dni, pri čemer je bilo ugotovljeno, da je večina poročanih neželenih učinkov in lokalnih reakcij na koži blage ali zmerne intenzivnosti ter, da so izzveneli brez posledic.
Safety of ReFacto AF was evaluated in previously treated children and adolescents (n=18, age 12-16 years in a study and n=49, age 7-16 years in a supporting study).
Varnost zdravila ReFacto AF so ovrednotili pri predhodno zdravljenih otrocih in mladostnikih (n = 18, starost 12-16 let v študiji in n = 49, starost 7-16 let v podporni študiji).
Safety Pharmacology
Varnostna farmakologija
Safety pharmacology studies have demonstrated no effects on the respiratory, central nervous or cardiovascular system.
Študije o farmakološki varnosti niso pokazale učinkov na dihala, osrednje živčevje ali na srčnožilni sistem.
Safety pharmacology studies have shown that Carbaglu administered orally at doses of 250, 500, 1000 mg/kg had no statistically significant effect on respiration, central nervous system and cardiovascular system.
V študijah farmakološke varnosti niso ugotovili, da bi zdravilo Carbaglu v peroralnih odmerkih po 250, 500 in 1.000 mg/kg imel statistično pomembne učinke na dihala, osrednji živčni sistem in srčno- žilni sistem.
Safety pharmacology studies showed no effect of agomelatine on hERG (human Ether à-go-go Related Gene) current or on dog Purkinje cells action potential.
Farmakološke študije o varnosti niso pokazale učinka agomelatina na hERG (human Ether à-go-go Related Gene) tok ali na akcijski potencial Purkynjevih celic pri psih.
Safety Phase Weeks 26-78 N (%)
Faza varnosti Tedni 26–78 N (%)
Safety population, on treatment
skupina preizkušancev za oceno varnosti zdravila, zdravljena
Safety results are expressed as the number of patients with an adverse reaction per 100 patient- years of exposure (except for injection site reactions).
Podatki o varnosti so izraženi kot število bolnikov z neželenim učinkom na 100 bolnikovih let izpostavljenosti (razen za reakcije na mestu injiciranja).
Safety trials have shown that the strain is safe for turkeys.
Varnostni poskusi kažejo, da je sev za purane varen.
Safety updates to coincide with PSUR timetable.
Posodobitev varnostnega profila sočasno s časovnico PSUR.
Safety was also demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses of up to 3 times the maximum recommended dose.
Prav tako je bila varnost ugotovljena pri vzrejnih in brejih živalih ter živalih v laktaciji, ki so bile zdravljene v 28-dnevnih intervalih z več zaporednimi odmerki do 3-kratnega največjega priporočenega odmerka.
Safety was assessed in a controlled clinical study enrolling renal transplant patients below 18 years of age considered of high immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy (see section 5.1).
Varnost so ocenjevali v kontrolirani klinični študiji, v katero so bili vključeni bolniki, mlajši od 18 let, po presaditvi ledvic, z velikim imunološkim tveganjem, kar pomeni z anamnezo ene ali več akutnih epizod zavrnitve alografta in/ali prisotnost kronične nefropatije alografta ob ledvični biopsiji (glejte poglavje 5.1).
Safety was considered acceptable, provided agreed measures were followed.
Varnost je bila ocenjena kot sprejemljiva, če se upoštevajo dogovorjeni ukrepi.
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses of up to 3 times the maximum recommended dose.
Varnost uporabe je bila ugotovljena pri vzrejnih in brejih živalih ter živalih v laktaciji, ki so bile zdravljene v 28-dnevnih intervalih z več zaporednimi odmerki do 3-kratnega največjega priporočenega odmerka.
Safety was demonstrated in breeding, pregnant and lactating animals treated with overdoses of up to 3 times the maximum recommended dose.
Varnost je bila dokazana pri živalih za vzrejo in pri živalih v obdobju brejosti in laktacije, ki so jim dajali odmerke, ki so bili do 3krat večji od največjega priporočenega odmerka.
Safety was demonstrated in puppies aged 8–9 weeks and weighing 2.0–3.6 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Varnost je bila dokazana pri psičkih, starih 8-9 tednov in težkih 2,0-3,6 kg, ki so jim dajali odmerke, ki so bili do 5krat večji od priporočenega odmerka, trikrat v krajših razmikih, kot je priporočeno (8- tedenski razmiki).
Safety was demonstrated in puppies aged 8–9 weeks and weighing 2.0–3.7 kg treated with overdoses of up to 5 times the maximum recommended dose on three occasions at shorter intervals than recommended (8-week intervals).
Varnost je bila dokazana pri psičkih, starih 8-9 tednov in težkih 2,0-3,6 kg, ki so jim dajali odmerke, ki so bili do 5krat večji od priporočenega odmerka, trikrat v krajših razmikih, kot je priporočeno (8- tedenski razmiki).
Safety was evaluated in an observational study that included 69,237 children vaccinated with ProQuad 12 months to 12 years old and 69,237 matched children in a historical comparison group who were vaccinated concomitantly with the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc., and the Varicella Vaccine live (Oka/Merck).
Varnost so ocenili v opazovalni študiji, ki je vključevala 69.237 otrok, cepljenih s cepivom ProQuad, starih od 12 mesecev do 12 let, ter 69.237 primerljivih otrok v historični primerjalni skupini, ki so bili sočasno cepljeni s cepivom proti ošpicam, mumpsu in rdečkam, izdelovalca Merck & Co., Inc., in s cepivom z živim virusom noric (Oka/Merck).
Safety was evaluated using vaccination report card (VRC)-aided surveillance for 14 days after each injection of Gardasil 9.
Varnost so ovrednotili s 14-dnevnim spremljanjem po vsaki injekciji cepiva Gardasil 9 na podlagi izkaznic o cepljenju (VRC – vaccination report card).
safety when
varnost sočasnega
Safety, efficacy, and pharmacokinetics of Pergoveris in patients with renal or hepatic impairment have not been established.
Varnost, učinkovitost in farmakokinetika zdravila Pergoveris pri bolnikih z okvaro ledvic ali jeter niso bile dokazane.
safety, have not been
klinični podatki kažejo, da
Safinamide
Safinamid
Safinamide absorption is rapid after single and multiple oral dosing, reaching Tmax in the time range 1.8-2.8 h after dosing under fasting conditions.
Absorpcija safinamida je po enkratnem in večkratnem peroralnem odmerjanju hitra, saj doseže Tmax v časovnem razponu 1,8-2,8 ure po odmerjanju na tešče.
Safinamide exposure in patients with mild hepatic disease increased marginally (30% in AUC), while in patients with moderate hepatic impairment exposure increased by approximately 80% (see section 4.2).
Izpostavljenost safinamidu pri bolnikih z blago jetrno okvaro se je rahlo povečala (30 % AUC), medtem ko se je pri bolnikih z zmerno jetrno okvaro izpostavljenost povečala za približno 80 % (glejte poglavje 4.2).
Safinamide is associated with state-dependent inhibition of voltage-gated sodium (Na+) channels, and modulation of stimulated release of glutamate.
Safinamid je povezan z od stanja odvisnim zaviranjem napetostno odvisnih natrijevih (Na+) kanalčkov na način in modulacijo stimuliranega sproščanja glutamata.
Safinamide is expected to be excreted in milk as adverse reactions have been observed in rat pups exposed via milk (see section 5.3).
Pričakuje se izločanje safinamida v materino mleko, saj so pri podganjih mladičih, ki so bili izpostavljeni prek mleka, opazili neželene reakcije (glejte poglavje 5.3).
Safinamide transiently inhibits BCRP in the small intestine (see section 4.5). .
Safinamid prehodno zavira BCRP v tankem črevesu (glejte poglavje 4.5).
Safinamide used as an adjunct to levodopa may potentiate the side effects of levodopa, and pre- existing dyskinesia may be exacerbated, requiring a decrease of levodopa.
Safinamid, ki je uporabljen kot dodatek k levodopi, lahko potencira neželene učinke levodope in poslabša predobstoječo diskinezijo, zaradi česar je potrebno zmanjšanje odmerka levodope.
Safinamide’s metabolism is not dependent on Cytochrome P450 (CYP) based enzymes.
Presnova safinamida ni odvisna od encimov, ki temeljijo na citokromu P450 (CYP).
Sage House 1st Floor, 319 Pinner Road North Harrow, Middlesex HA1 4HF United Kingdom
Sage House 1st Floor, 319 Pinner Road North Harrow, Middlesex HA1 4HF Združeno kraljestvo
Sage house, 319 Pinner Road, Harrow HA1 4HF, United Kingdom or
Sage house, 319 Pinner Road, Harrow HA1 4HF, Velika Britanija ali
Sage House, 319 Pinner Road, North Harrow, HA1 4 HF, Middlesex United Kingdom
Sage House, 319 Pinner Road, North Harrow, HA1 4 HF, Middlesex Velika Britanija
Sage house, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, United Kingdom
Sage house, 319 Pinner Road, North Harrow, Middlesex HA1 4HF, Velika Britanija
Salamanca 37080 Spain
Salamanca 37080 Španija
Salicylates (e.g. aspirin)
alicilate (npr. aspirin),
Salicylates (e.g. aspirin).
alicilate (npr. aspirin),
Salicylates (used to relieve pain and lower fever)
alicilate (uporabljajo se za lajšanje bolečine in znižanje zvišane telesne temperature),
Salicylates (used to relieve pain and lower fever)
alicilate (uporabljamo jih za lajšanje bolečine in znižanje zvišane telesne temperature),
Saline buffer
Puferska raztopina
Saline buffer
Pufrska raztopina
Salivary hypersecretion
Prekomerno izločanje sline
Salivary hypersecretion
Čezmerno izločanje sline
Salivary hypersecretion Dysgeusia
Prekomerno izločanje sline
Salivation, vomiting and neurological signs (tremor) were observed occasionally when the product was administered at up to 10 times the recommended dose in adult cats and up to 5 times the recommended dose in kittens.
Pri nanosu desetkratnega terpevtskega odmerka odraslim mačkam ter petkratnega terapevtskega odmerka mačjim mladičem, se je občasno pojavilo slinjenje, bruhanje ter nevrološki znaki npr. drget.
Salivation, vomiting and trembling were observed occasionally when the product was administered at up to 10 times the recommended dose in adult cats and up to 5 times the recommended dose in kittens.
Pri nanosu desetkratnega terapevtskega odmerka odraslim mačkam ter petkratnega terapevtskega odmerka mačjim mladičem, se je občasno pojavilo slinjenje, bruhanje ter nevrološki znaki npr. drget.
Salmeterol
Antipsihotiki
Salmeterol
rifabutin,
Salmeterol (medicine to treat asthma)
almeterol (zdravilo za zdravljenje astme)
Salmeterol 50 twice a day
almeterol
Salmeterol is a long-acting bronchodilator.
Salmeterol je dolgodelujoči bronhodilatator.
Salmeterol Ritonavir inhibits CYP3A4 and as a result a pronounced increase in the plasma concentrations of salmeterol is expected.
Ritonavir zavira CYP3A4 in pričakovati je treba izrazito zvišanje koncentracije salmeterola v plazmi.
Salmeterol/fluticasone propionate 50/500
Salmeterol/flutikazon- propionat 50/500